Cas no 113806-05-6 (Olopatadine)

Olopatadine is a selective histamine H1 antagonist and mast cell stabilizer, primarily used in ophthalmic solutions to treat allergic conjunctivitis. Its dual mechanism of action inhibits both the release of inflammatory mediators from mast cells and the binding of histamine to H1 receptors, providing rapid and sustained relief from itching, redness, and swelling. Olopatadine exhibits high receptor affinity and low systemic absorption, minimizing adverse effects. Its efficacy and tolerability make it a preferred choice for managing ocular allergies in both adults and children. The compound is also available in nasal formulations for allergic rhinitis, demonstrating its versatility in allergy management.

Olopatadine structure

Product Name:Olopatadine

CAS No:113806-05-6

MF:C₂₁H₂₃NO₃

MW:337.412225961685

MDL:MFCD00865645

CID:63038

PubChem ID:5281071

Update Time:2025-06-07

Olopatadine Chemical and Physical Properties

Names and Identifiers

- Olopatadine Hydrochloride
- Olopatadine hcl
- 11-((z)-3-(dimethyl-amino)propylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid
- OLOPATADINE
- Olopatatadine
- KW 4679
- Dibenz[b,e]oxepin-2-acetic acid, 11-[3-(dimethylamino)propylidene]-6,11-dihydro-, (11Z)-
- {(11Z)-11-[3-(dimethylamino)propylidene]-6,11-dihydrodibenzo [b,e]oxepin-2-yl}acetic acid
- a-Hydroxy-Olopatadine
- -2-(11-(3-(Dimethylamino)
- Olopatadine & Olopatadine Hydrochloride
- BCP12203
- 2-[(2Z)-2-[3-(dimethylamino)propylidene]-9-oxatricyclo[9.4.0.0,3,8]pentadeca-1(11),3(8),4,6,12,14-hexaen-5-yl]acetic acid
- D27V6190PM
- AM84372
- CHEBI:94593
- AB00698500-07
- AB00698500-10
- D08293
- BRD-K37130586-003-01-3
- Olopatadina
- UNII-D27V6190PM
- HY-W062109
- AKOS025149450
- AB00698500_11
- SR-01000763388-3
- (Z)-2-(11-(3-(Dimethylamino)propylidene)-6,11-dihydrodibenzo[b,e]oxepin-2-yl)acetic acid
- L000748
- 113805-63-3
- Patanol
- MLS006011811
- AKOS005557129
- Q3267092
- EN300-6482051
- Olopatadine [INN:BAN]
- R01AC08
- C07789
- DB00768
- BIDD:GT0285
- DTXSID3023390
- 2-[(11E)-11-[3-(dimethylamino)propylidene]-6H-benzo[c][1]benzoxepin-2-yl]acetic acid;Olopatadine
- (E)-2-(11-(3-(dimethylamino)propylidene)-6,11-dihydrodibenzo[b,e]oxepin-2-yl)aceticacid
- Opatanol
- OLOPATADINE [WHO-DD]
- Olopatadin
- GTPL7249
- BRD-K67637637-003-12-6
- AL-4943A
- DIBENZ(B,E)OXEPIN-2-ACETIC ACID, 11-(3-(DIMETHYLAMINO)PROPYLIDENE)-6,11-DIHYDRO-, (Z)-
- 11-(3-(dimethylamino)propylidene)-6,11-dihydrodibenz(b,e)oxepin-2-acetic acid
- S01GX09
- NS00000615
- JBIMVDZLSHOPLA-LSCVHKIXSA-N
- SMR004703490
- SCHEMBL4668
- Olopatadinum
- SR-01000763388
- 2-[(2Z)-2-[3-(dimethylamino)propylidene]-9-oxatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,12,14-hexaen-5-yl]acetic acid
- CHEMBL1189432
- BS-42100
- OLOPATADINE [INN]
- DTXCID603390
- AB00698500-09
- CS-0053963
- [11-(3-Dimethylamino-propylidene)-6,11-dihydro-dibenzo[b,e]oxepin-2-yl]-acetic acid; hydrochloride
- 113806-05-6
- HMS2089K10
- 2-[(11Z)-11-[3-(dimethylamino)propylidene]-6H-benzo[c][1]benzoxepin-2-yl]acetic acid
- BDBM50002096
- A803097
- CHEMBL1719
- Olopatadine (INN)
- 11-((Z)-3-(Dimethylamino)propylidene)-6,11-dihydrodibenz(b,e)oxepin-2-acetic acid
- (z)-11-(3-(dimethyl-amino)-propylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid
- OLOPATADINE [VANDF]
- OLOPATADINE [MI]
- {(11Z)-11-[3-(dimethylamino)propylidene]-6,11-dihydrodibenzo[b,e]oxepin-2-yl}acetic acid
- STK624184
- (Z)-11-[3-(Dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic Acid; 11-[(Z)-3-(Dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic Acid; Opatanol; Pataday; Patanol
- Olopatadine
- MDL： MFCD00865645
- Inchi： 1S/C21H23NO3/c1-22(2)11-5-8-18-17-7-4-3-6-16(17)14-25-20-10-9-15(12-19(18)20)13-21(23)24/h3-4,6-10,12H,5,11,13-14H2,1-2H3,(H,23,24)/b18-8-
- InChI Key： JBIMVDZLSHOPLA-LSCVHKIXSA-N
- SMILES： O1CC2C=CC=CC=2/C(=C/CCN(C)C)/C2C=C(CC(=O)O)C=CC1=2

Computed Properties

Exact Mass: 337.16800
Monoisotopic Mass: 337.168
Isotope Atom Count: 0
Hydrogen Bond Donor Count: 1
Hydrogen Bond Acceptor Count: 4
Heavy Atom Count: 25
Rotatable Bond Count: 5
Complexity: 488
Covalently-Bonded Unit Count: 1
Defined Atom Stereocenter Count: 0
Undefined Atom Stereocenter Count : 0
Defined Bond Stereocenter Count: 1
Undefined Bond Stereocenter Count: 0
XLogP3: 1.5
Topological Polar Surface Area: 49.8A^2

Experimental Properties

Color/Form: Solid
Density: 1.2±0.1 g/cm3
Melting Point: 188-194°C
Boiling Point: 523.0±50.0 °C at 760 mmHg
Flash Point: 270.1±30.1 °C
PSA: 49.77000
LogP: 3.58950
Vapor Pressure: 0.0±1.4 mmHg at 25°C

Olopatadine Security Information

Signal Word：Danger
Hazard Statement： H301; H410
Warning Statement： P264; P270; P273; P301+P310; P321; P330; P391; P405; P501
Safety Instruction： H303May be harmful if swallowed+H313Skin contact may be harmful+H333Inhalation may be harmful to the body
HazardClass：6.1
PackingGroup：III
Storage Condition：Store at room temperature

Olopatadine Pricemore >>

Related Categories	No.	Product Name	Cas No.	Purity	Specification	Price	update time
TRC	O574995-25mg	Olopatadine	113806-05-6		25mg	$ 127.00	2023-09-06
TRC	O574995-50mg	Olopatadine	113806-05-6		50mg	$ 224.00	2023-04-15
TRC	O574995-100mg	Olopatadine	113806-05-6		100mg	$ 397.00	2023-09-06
TRC	O574995-250mg	Olopatadine	113806-05-6		250mg	$ 896.00	2023-04-15
Alichem	A019095690-1g	(Z)-2-(11-(3-(Dimethylamino)propylidene)-6,11-dihydrodibenzo[b,e]oxepin-2-yl)acetic acid	113806-05-6	97%	1g	$920.82	2023-09-04
eNovation Chemicals LLC	D761754-5mg	Dibenz[b,e]oxepin-2-acetic acid, 11-[3-(dimethylamino)propylidene]-6,11-dihydro-, (11Z)-	113806-05-6	98.0%	5mg	$165	2024-06-08
eNovation Chemicals LLC	D761754-25mg	Dibenz[b,e]oxepin-2-acetic acid, 11-[3-(dimethylamino)propylidene]-6,11-dihydro-, (11Z)-	113806-05-6	98.0%	25mg	$370	2024-06-08
SHANG HAI HAO HONG Biomedical Technology Co., Ltd.	1124603-25mg	Olopatadine	113806-05-6	98%	25mg	￥2470	2023-04-17
Enamine	EN300-6482051-0.05g	2-[(2Z)-2-[3-(dimethylamino)propylidene]-9-oxatricyclo[9.4.0.0,3,8]pentadeca-1(15),3,5,7,11,13-hexaen-5-yl]acetic acid	113806-05-6		0.05g	$29.0	2023-05-31
Enamine	EN300-6482051-0.1g	2-[(2Z)-2-[3-(dimethylamino)propylidene]-9-oxatricyclo[9.4.0.0,3,8]pentadeca-1(15),3,5,7,11,13-hexaen-5-yl]acetic acid	113806-05-6		0.1g	$30.0	2023-05-31

Olopatadine Production Method

Olopatadine Suppliers

Tiancheng Chemical (Jiangsu) Co., Ltd

Gold Member

Audited Supplier

(CAS:113806-05-6)Olopatadine

Order Number:LE16024;LE26820202

Stock Status:in Stock

Quantity:25KG,200KG,1000KG

Purity:99%

Pricing Information Last Updated:Friday, 20 June 2025 12:13

Price ($):discuss personally

Email:[email protected]

Olopatadine Related Literature

1. The Mizoroki–Heck reaction between in situ generated alkenes and aryl halides: cross-coupling route to substituted olefins

Anushka Koranne,Shrishty Turakhia,Vikesh Kumar Jha,Sangeeta Gupta,Rangnath Ravi,Abhijeet Mishra,Anil K. Aggarwal,Chandan Kumar Jha,Neelu Dheer,Abadh Kishor Jha RSC Adv. 2023 13 22512

Related Categories

Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzoxepines Dibenzoxepines

Additional information on Olopatadine

Olopatadine: A Comprehensive Overview

Olopatadine, also known by its CAS number 113806-05-6, is a widely recognized and effective medication primarily used in the treatment of allergic conditions. It belongs to the class of second-generation antihistamines, which are known for their ability to block histamine H1 receptors without causing significant sedation. This makes it particularly suitable for patients who require a non-sedating antihistamine for the management of allergic symptoms such as sneezing, itching, and runny nose.

The chemical structure of Olopatadine (CAS 113806-05-6) is characterized by its unique ability to selectively inhibit histamine activity. Unlike first-generation antihistamines, which often cross the blood-brain barrier and cause drowsiness, Olopatadine is designed to remain in the periphery, minimizing central nervous system effects. This property has made it a preferred choice for both adults and children suffering from seasonal and perennial allergies.

Recent studies have highlighted the efficacy of Olopatadine in treating allergic conjunctivitis, a condition characterized by eye redness and itching. Research published in 2023 demonstrated that Olopatadine eye drops provide rapid relief from symptoms, with significant improvements observed within 30 minutes of administration. This finding underscores its role as a first-line treatment for ocular allergies.

In addition to its antihistaminic properties, Olopatadine has also been shown to possess anti-inflammatory effects. This dual mechanism of action makes it particularly effective in managing moderate to severe allergic reactions. A 2022 clinical trial comparing Olopatadine with other antihistamines found that it exhibited superior efficacy in reducing inflammation markers such as interleukin-4 and interleukin-13.

The pharmacokinetics of Olopatadine (CAS 113806-05-6) are well-documented. When administered orally, it is rapidly absorbed into the bloodstream, with peak plasma concentrations achieved within 1-2 hours. Its half-life of approximately 9 hours allows for twice-daily dosing, ensuring consistent symptom control throughout the day. The drug is primarily metabolized in the liver and excreted through urine, making it suitable for patients with normal renal function.

One of the most recent advancements in Olopatadine research involves its use in combination therapies. A 2023 study explored the efficacy of combining Olopatadine with corticosteroids in treating severe allergic rhinitis. The results indicated that this combination significantly reduced nasal congestion and improved quality of life scores compared to monotherapy.

Despite its numerous benefits, it is important to consider the safety profile of Olopatadine. Common side effects include mild gastrointestinal discomfort and headache, which are generally well-tolerated. Rarely, patients may experience dizziness or dry mouth. Long-term studies have shown that Olopatadine does not pose significant risks when used as directed, making it a safe option for chronic allergy management.

In conclusion, Olopatadine (CAS 113806-05-6) stands out as a versatile and effective medication in the realm of allergy treatment. Its unique pharmacological properties, combined with recent research findings, solidify its position as a cornerstone in modern allergology. Whether used orally or topically, Olopatadine continues to provide reliable relief for millions of allergy sufferers worldwide.

113806-05-6 (Olopatadine) Related Products

Recommended suppliers